SynthesisJournal of orthopaedic surgery and research2025
NOACs for VTE prevention in patients with lower limb fracture: a systematic review and meta-analysis.
Synthesis in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNovel oral anticoagulants (NOACs), including rivaroxaban, apixaban, edoxaban and dabigatran, are increasingly used for orthopaedic surgery patients. The aim of this study was to evaluate the efficacy and safety of NOACs in preventing venous thromboembolism (VTE) among patients with lower limb fractures. MATERIALS AND
methodsThis meta-analysis included randomized controlled trials (RCTs). The PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched from inception to November 27, 2024. We evaluated the risk of bias via the Cochrane Risk of Bias Tool 2.0 (RoB 2.0). The efficacy outcomes focused on VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE), and the safety outcomes focused on major bleeding events. Two researchers screened the literature on the basis of the inclusion and exclusion criteria, evaluated the quality of the included studies, extracted the data, and conducted a meta-analysis using RevMan 5.4.1.
resultsThe systematic search yielded 2,873 unique citations after deduplication. Ultimately, five RCTs involving 4,092 participants (2,066 participants in the NOAC group (rivaroxaban and edoxaban) and 2,026 participants in the LMWH group) were included. Pooled analysis revealed that NOACs reduced the incidence rate of DVT [OR = 0.48, 95% CI (0.23-0.97), P = 0.04; I²=10%]. However, there was no significant difference in the incidence of VTE [OR = 0.42, 95% CI (0.16-1.11), P = 0.08; I²=34%], PE [OR = 0.33, 95% CI (0.05-2.08), P = 0.24; I²=0%] or major bleeding [OR = 1.01, 95% CI (0.57-1.77), P = 0.98; I²=0%] between the LMWH group and the NOACs group.
conclusionsCompared with LMWH, NOACs were associated with a lower risk of DVT in patients with lower limb fractures, although there was no statistically significant difference in preventing VTE, PE and major bleeding. CLINICAL TRAIL NUMBER: No. CRD42024619453.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.